Analyzing Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock’s Performance and Trends for Investment

In the last trading session, 1.58 million Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares changed hands as the company’s beta touched -0.55. With the company’s per share price at $5.52 changed hands at $0.16 or 2.99% during last session, the market valuation stood at $492.06M. AMLX’s last price was a discount, traded about -31.7% off its 52-week high of $7.27. The share price had its 52-week low at $1.58, which suggests the last value was 71.38% up since then.

Analysts gave the Amylyx Pharmaceuticals Inc (AMLX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AMLX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information

Instantly AMLX was in green as seen at the end of in last trading. With action 22.94%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 46.03%, with the 5-day performance at 22.94% in the green. However, in the 30-day time frame, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) is 30.50% up.

The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 44.8% from its current market value. According to analyst projections, AMLX’s forecast low is 10 with 10 as the target high. To hit the forecast high, the stock’s price needs a -81.16% plunge from its current level, while the stock would need to soar -81.16% for it to hit the projected low.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -78.71%. The 2025 estimates are for Amylyx Pharmaceuticals Inc earnings to increase by 60.59%, but the outlook for the next 5-year period is at 29.16% per year.

AMLX Dividends

Amylyx Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.

AQR CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 4.9114% or 3.34 million shares worth $6.35 million as of 2024-06-30.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.